CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
批准号:
2896933
负责人:
Philip A Osdoby
金额:
$20.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-30 至 2003-07-31
关键词:
RNase protection assay acid phosphatase biological signal transduction bone disorder cell cell interaction cell differentiation cell growth regulation chickens congenital oral /facial /cranial defect cytokine receptors enzyme linked immunosorbent assay gene targeting genetically modified animals human tissue immunocytochemistry in situ hybridization interleukin 8 laboratory mouse monoclonal antibody neutralizing antibody osteoclasts osteogenesis pathologic bone resorption physiologic bone resorption polymerase chain reaction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Normal bone development and remodeling require complex humoral, cell-
cell, and cell-matrix interactions. The integration of humoral and
local signals is necessary to permit proper development, maintain
mineral homeostasis, insure mechanical strength, and support
haematopoeisis. There is now good evidence that osteoblasts can
orchestrate osteoclast development and modulate osteoclast activity via
paracrine signals. Information is just beginning to emerge that
osteoclasts themselves synthesize and release factors that may influence
bone remodeling. We therefore hypothesize that osteoclast-derived
signals may function as autocrine effectors of osteoclast development
and activity and therefore influence normal and pathological
osteoclastogenesis and osteoclast-mediated bone resorption. We have
shown that osteoclasts produce small proinflammatory molecules known as
chemokines, such as IL-8 and GRO alpha and that such molecules can act
to modulate osteoclast precursor recruitment, development, and activity.
Therefore, to further investigate and define osteoclast autocrine
regulation we propose the following specific aims: 1) Identify a profile
of chemokines produced by human and mouse OC and determine which exhibit
autocrine effects on OC function (bone resorption, motility, free
radical production, TRAP, cathepsin K, and carbonic anhydrase II
expression). The regulation of this subset of chemokines by select
known modulators of OC function will be analyzed. Included here will be
studies employing selective chemokine and chemokine receptor
antagonists, chemokine neutralizing antibodies, and mouse OC-like cells
formed in vitro from bone marrow obtained from IL-8 receptor knockout
mice. 2) Identify and characterize the profile of chemokine receptors
expressed on OC as a function of OC physiology, and pathophysiology.
As part of this aim we will begin to elucidate the intracellular signal
transduction pathways involved in chemokine modulation of OC activity.
3) Examine the potential role of chemokines in OC precursor recruitment
and differentiation in vitro, in vivo, and in ovo. 4. Examine spatial
and temporal aspects of chemokine and chemokine receptor expression in
normal and pathological bone tissue by in situ hybridization and
immunohistochemistry. Included here are mouse IL-8 receptor knockout
studies. All of the above studies will use a combination of in vivo and
in vitro approaches, and model systems including the mouse calvarial
injection model for histomorphometric studies, human tissue sections for
in situ hybridization and immunohistochemical analysis, isolated human
and avian Ocs, human Oc-like cells, the mouse Oc-like cell developmental
model, and cells obtained from an IL-8 receptor knockout mouse. Oc-
chemokine production, mRNA steady state levels and regulation will be
assessed by RT-PCP, RNAse protection assay, chemokine ELISA, and in situ
hybridization techniques. Osteoclast development and activity will be
evaluated based on functional, biochemical and molecular markers of the
osteoclast phenotype, including bone resorption, osteoclast antigen
expression tartarate-resistant acid phosphatase activity, and calcitonin
receptor levels. Such studies are anticipated to reveal new aspects of
normal bone remodeling mechanisms such as tooth eruption and have
potential to lend insight into skeletal pathologies such as periodontal
disease, implant loosening, osteoarthritis, other inflammatory skeletal
disorders, and osteoporosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OSTEOGENESIS IMPERFECTA, AND NITRIC OXIDE THERAPY
-
批准号:7318366
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2007
-
负责人:Philip A Osdoby
-
依托单位:
OSTEOGENESIS IMPERFECTA, AND NITRIC OXIDE THERAPY
-
批准号:7477733
-
项目类别:
-
资助金额:$16.01万
-
财政年份:2007
-
负责人:Philip A Osdoby
-
依托单位:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
-
批准号:6374990
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2000
-
负责人:Philip A Osdoby
-
依托单位:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
-
批准号:6652038
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2000
-
负责人:Philip A Osdoby
-
依托单位:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
-
批准号:6534426
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2000
-
负责人:Philip A Osdoby
-
依托单位:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
-
批准号:6287613
-
项目类别:
-
资助金额:$21.77万
-
财政年份:2000
-
负责人:Philip A Osdoby
-
依托单位:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
-
批准号:6796894
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2000
-
负责人:Philip A Osdoby
-
依托单位:
OSTEOCLAST MEDIATED BONE REMODELING
-
批准号:6338643
-
项目类别:
-
资助金额:$24.58万
-
财政年份:2000
-
负责人:Philip A Osdoby
-
依托单位:
OSTEOCLAST MEDIATED BONE REMODELING
-
批准号:6100405
-
项目类别:
-
资助金额:$24.58万
-
财政年份:1999
-
负责人:Philip A Osdoby
-
依托单位:
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
-
批准号:6379723
-
项目类别:
-
资助金额:$21.71万
-
财政年份:1998
-
负责人:Philip A Osdoby
-
依托单位:
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
-
批准号:6523818
-
项目类别:
-
资助金额:$22.36万
-
财政年份:1998
-
负责人:Philip A Osdoby
-
依托单位:
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
-
批准号:2693792
-
项目类别:
-
资助金额:$20.72万
-
财政年份:1998
-
负责人:Philip A Osdoby
-
依托单位:
OSTEOCLAST MEDIATED BONE REMODELING
-
批准号:6268337
-
项目类别:
-
资助金额:$25.28万
-
财政年份:1998
-
负责人:Philip A Osdoby
-
依托单位:
CELLULAR BASIS OF CRANIOFACIAL BONE DISORDERS
-
批准号:6175810
-
项目类别:
-
资助金额:$21.08万
-
财政年份:1998
-
负责人:Philip A Osdoby
-
依托单位:
CELL SURFACE AND OSTEOCLAST DEVELOPMENT
-
批准号:2748570
-
项目类别:
-
资助金额:$24.16万
-
财政年份:1997
-
负责人:Philip A Osdoby
-
依托单位:
CELL SURFACE AND OSTEOCLAST DEVELOPMENT
-
批准号:2609895
-
项目类别:
-
资助金额:$23.45万
-
财政年份:1997
-
负责人:Philip A Osdoby
-
依托单位:
CELL SURFACE AND OSTEOCLAST DEVELOPMENT
-
批准号:6169154
-
项目类别:
-
资助金额:$25.63万
-
财政年份:1997
-
负责人:Philip A Osdoby
-
依托单位:
CELL SURFACE AND OSTEOCLAST DEVELOPMENT
-
批准号:6043107
-
项目类别:
-
资助金额:$24.88万
-
财政年份:1997
-
负责人:Philip A Osdoby
-
依托单位:
OSTEOCLAST MEDIATED BONE REMODELING
-
批准号:6235703
-
项目类别:
-
资助金额:$22.75万
-
财政年份:1997
-
负责人:Philip A Osdoby
-
依托单位:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
-
批准号:2082147
-
项目类别:
-
资助金额:$18.39万
-
财政年份:1996
-
负责人:Philip A Osdoby
-
依托单位:
海外基金